AXDXAccelerate Diagnostics, Inc

Nasdaq acceleratediagnostics.com


$ 0.91 $ 0.01 (1.23 %)    

Monday, 13-May-2024 12:13:01 EDT
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 0.891
$ 0.89
$ 0.00 x 0
$ 0.00 x 0
$ 0.89 - $ 0.91
$ 0.73 - $ 11.90
6,235
na
17.12M
$ 1.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 03-02-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 02-28-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-01-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-01-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-09-2016 12-31-2015 10-K
35 11-02-2015 09-30-2015 10-Q
36 07-31-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-26-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-01-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 accelerate-diagnostics-q1-2024-gaap-eps-088-misses-072-estimate-sales-2921m-miss-3000m-estimate

Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate...

 craig-hallum-maintains-hold-on-accelerate-diagnostics-lowers-price-target-to-1

Craig-Hallum analyst Alexander Nowak maintains Accelerate Diagnostics (NASDAQ:AXDX) with a Hold and lowers the price target ...

 accelerate-diagnostics-q4-eps-089-misses-062-estimate-sales-303m-miss-345m-estimate

Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

 why-accelerate-diagnostics-axdx-stock-is-down-38

Accelerate Diagnostics shares are trading lower by 38% during Friday's session. The company priced an underwritten public o...

 us-stocks-higher-schlumberger-earnings-beat-estimates

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market o...

 accelerate-diagnostics-announces-pricing-of-15m-public-offering-and-private-placement-the-public-offering-price-for-each-unit-is-150-and-the-public-offering-price-for-each-pre-funded-unit-is-149

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (the "Company") today announced the pricing of an underwritten public offeri...

 why-accelerate-diagnostics-axdx-stock-hit-a-new-52-week-low-today

Accelerate Diagnostics shares are trading lower by 23.2% Tuesday morning. The company announced the initiation of a proposed un...

 accelerate-diagnostics-has-launched-a-proposed-underwritten-public-offering-of-45m-each-consisting-of-one-share-of-common-stock-and-one-warrant-to-purchase-one-share-of-common-stock-terms-not-disclosed

The Company expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock an...

 accelerate-diagnostics-announces-certain-preliminary-q4-and-fy23-results-fy23-preliminary-revenue-was-121m-vs-128m-yoy-ended-the-year-with-134m-in-cash-and-cash-equivalents

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that i...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION